To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis
Status:
Completed
Trial end date:
2020-05-26
Target enrollment:
Participant gender:
Summary
To demonstrate non-inferiority in efficacy of FE 999315 to mesalazine in patients with mild
to moderate active ulcerative colitis after 8 weeks of treatment.